Bhavana Bhatnagar

Bhavana Bhatnagar, DO

Osteopathic Physician

Make an Appointment


Overall Patient Satisfaction Rating

4.8 out of 5




I’m a hematologist specializing in acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, myelodysplastic syndromes and other blood cancers. I attended medical school at the Philadelphia College of Osteopathic Medicine and completed my internal medicine internship and residency at the Cleveland Clinic and my hematology and medical oncology fellowship at the University of Maryland Marlene and Stewart Greenebaum Cancer Center. I am currently an assistant professor of Internal Medicine in the Division of Hematology here at Ohio State. I was rated in the top 10 percent of physicians in the nation for patient satisfaction in 2016.

In my research, I examine novel experimental treatments that may bring us closer to finding cures for cancer. In addition to being published more than a dozen times, I have been fortunate to present my research findings at hospitals across the country. I also serve as a member of the American Society of Hematology, the American Society of Clinical Oncology and as a panel member for the National Comprehensive Cancer Network.

Education and Background


Philadelphia College of Osteopathic Medicine

Philadelphia, PA


Cleveland Clinic Foundation

Cleveland, OH



University of Maryland Medical Center

Baltimore, MD

Board Certifications

American Board of Internal Medicine

American Board of Internal Medicine

American Board of Internal Medicine (Subspecialty: Hematology)

American Board of Internal Medicine (Subspecialty: Medicine Oncology)

American Board of Internal Medicine (Subspecialty: Medicine Oncology)

Academic Department

Department of Internal Medicine

Division of Hematology

Consulting and Related Relationships

At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 11/21/2019, Dr. Bhatnagar has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.

Astellas Pharma, Inc.


Patient Satisfaction Review

The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our Patient Satisfaction Survey page

The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.

Overall Ratings (out of 39 reviews)
4.8 out of 5
Kept you informed about your condition and treatment

4.7/ 5

Amount of time spent with you

4.6/ 5

Concern for your questions and issues

4.8/ 5

Skill and knowledge

4.9/ 5

Overall quality of care

4.9/ 5

Patient Comments (5 total comments)

Reviewed: 8/16/2019

Totally satisfied

Reviewed: 7/22/2019

Dr. Bhatnagar spent time getting to know my stepmother, making her feel at ease.

Reviewed: 6/4/2019

Dr. Bhathagar is amazing.

Reviewed: 4/25/2019

This facility have saved my life twice. They are the BEST!

Reviewed: 4/9/2019

Very good.


Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia.

Gopalakrishnan B, Cheney C, Mani R, Mo X, Bucci D, Walker A, Klisovic R, Bhatnagar B, Walsh K, Rueter B, Waizenegger IC, Heider KH, Blum W, Vasu S, Muthusamy N

Oncotarget 9


p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.

Zhang J, Kong G, Rajagopalan A, Lu L, Song J, Hussaini M, Zhang X, Ranheim EA, Liu Y, Wang J, Gao X, Chang YI, Johnson KD, Zhou Y, Yang D, Bhatnagar B, Lucas DM, Bresnick EH, Zhong X, Padron E, Zhang J

Blood 129


Clinical Trials | Lead




Back to Find a Doctor Search

Make an Appointment


Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator


Please enter a keyword (i.e. Name, Location) or choose a Cancer Type